Title : Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.

Pub. Date : 2022 May 20

PMID : 35417135






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 However, efforts to develop LXR agonists to reduce cardiovascular diseases have failed due to poor clinical outcomes-associated increased hepatic lipogenesis and elevated low-density lipoprotein (LDL) cholesterol (C). Cholesterol nuclear receptor subfamily 1, group H, member 3 Mus musculus
2 Here, we report that LXR inverse agonists are effective in lowering plasma LDL cholesterol and triglycerides in several models of hyperlipidemia, including the Ldlr null mouse model of atherosclerosis. Cholesterol nuclear receptor subfamily 1, group H, member 3 Mus musculus
3 Oral administration of a gut-specific LXR inverse agonist leads to reduction of Soat2 expression in the intestine and effectively lowers circulating LDL cholesterol and triglyceride levels without modulating LXR target genes in the periphery. Cholesterol nuclear receptor subfamily 1, group H, member 3 Mus musculus